Table 2.
Baseline characteristics: anemia prevalence and hemoglobin levels
| Study author, year | Country | Proportion of anemic women at baseline (%)–average of proportions in each study arm | Hemoglobin at baseline (g/L)–average of mean values in each study arm |
|---|---|---|---|
| Christian, 19 2003 | Nepal | 33.3 | 115.0 |
| Liu, 27 2013 | China | 5.0 | 122.0 |
| Moore, 28 2009 | The Gambia | 36.4 | 114.3 |
| Osrin, 40 2005 | Nepal | 38.0 | 115.0 |
| Ramakrishnan, 12 2003 | Mexico | 14.2 | 125.5 |
| Roberfroid, 39 2008 | Burkina Faso | 46.5 | 110.0 |
| SUMMIT, 20 2008 | Indonesia | 46.8 | 109.7 |
| Sunawang, 21 2009 | Indonesia | 37.5 | 113.0 |
| Tofail, 30 2008 (IFA 30 mg) | Bangladesh | 28.5 | 116.9 |
| Tofail, 30 2008 (IFA 60 mg) | Bangladesh | 28.5 | 116.6 |
| West, 22 2014 | Bangladesh | 21.7 | 117.6 |
| Zeng, 23 2008 | China | N.A. | N.A. |
note: The gestational time of baseline hemoglobin/anemia assessment (gestational age at enrollment) varied from 9 weeks in the trial West 2014 to 24 weeks in the trial Roberfroid. 39
N.A., not available.